Notice of Amendment: Revision of Brimonidine on the Prescription Drug List (PDL)

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing of "brimonidine or its salts" on the Prescription Drug List (PDL). Note that both the human and veterinary parts of the PDL were revised with the addition of a qualifier.

Données et ressources

Info additionnelle

Champ Valeur
Dernière modification avril 17, 2026, 17:40 (TU)
Créé le avril 17, 2026, 17:40 (TU)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2022-05-09 00:00:00
open_canada_keywords {"fr": ["notice of amendment", "prescription drug list", "PDL", "revision of brimonidine"], "en": ["notice of amendment", "prescription drug list", "PDL", "revision of brimonidine"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Avis de modification : révision de la brimonidine sur la Liste des drogues sur ordonnance
update_frequency as_needed